Læknablaðið - 15.06.2009, Síða 35

FRÆÐIGREINAR
Y F I R L I T
17. Montgomery AB, Mills J, Luce JM. Incidence of acute
mountain sickness at intermediate altitude. Jama 1989; 261:
732-4.
18. Hackett PH, Roach RC. High altitude cerebral edema. High
Alt Med Biol 2004;5:136-46.
19. Wu T, Ding S, Liu J, et al. Ataxia: an early indicator in high
altitude cerebral edema. High Alt Med Biol 2006; 7: 275-80.
20. Maggiorini M. High altitude-induced pulmonary oedema.
Cardiovasc Res 2006; 72: 41-50.
21. Grocott M, Montgomery H, Vercueil A. High-altitude
physiology and pathophysiology: implications and
relevance for intensive care medicine. Crit Care 2007; 11:
203.
22. West JB. The physiologic basis of high-altitude diseases. Ann
Intem Med 2004; 141: 789-800.
23. Duplain H, Sartori C, Lepori M, et al. Exhaled nitric oxide
in high-altitude pulmonary edema: role in the regulation
of pulmonary vascular tone and evidence for a role against
inflammation. Am J Respir Crit Care Med 2000; 162: 221-4.
24. Sartori C, Vollenweider L, Loffler BM, et al. Exaggerated
endothelin release in high-altitude pulmonary edema.
Circulation 1999; 99: 2665-8.
25. Rupert JL, Koehle MS. Evidence for a genetic basis for
altitude-related illness. High Alt Med Biol 2006; 7:150-67.
26. Moore LG. Human genetic adaptation to high altitude. High
Alt Med Biol 2001; 2: 257-79.
27. Montgomery H, Clarkson P, Bamard M, et al. Angiotensin-
converting-enzyme gene insertion/deletion polymorphism
and response to physical training. Lancet 1999; 353: 541-5.
28. Hanaoka M, Droma Y, Hotta J, et al. Polymorphisms of the
tyrosine hydroxylase gene in subjects susceptible to high-
altitude pulmonary edema. Chest 2003; 123: 54-8.
29. Droma Y, Hanaoka M, Ota M, et al. Positive association of
the endothelial nitric oxide synthase gene polymorphisms
with high-altitude pulmonary edema. Circulation 2002; 106:
826-30.
30. Cumbo TA, Basnyat B, Graham J, Lescano AG, Gambert
S. Acute mountain sickness, dehydration, and bicarbonate
clearance: preliminary field data from the Nepal Himalaya.
Aviat Space Environ Med 2002; 73:898-901.
31. Oelz O, Howald H, Di Prampero PE, et al. Physiological
profile of world-class high-altitude climbers. J Appl Physiol
1986; 60:1734-42.
32. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y,
Yeh C. Efficacy of low-dose acetazolamide (125 mg BID) for
the prophylaxis of acute mountain sickness: a prospective,
double-blind, randomized, placebo-controlled trial. High
Alt Med Biol 2003; 4:45-52.
33. Larson EB, Roach RC, Schoene RB, Hornbein TF. Acute
mountain sickness and acetazolamide. Clinical efficacy and
effect on ventilation. Jama 1982; 248: 328-32.
34. Luks AM, Swenson ER. Medication and dosage
considerations in the prophylaxis and treatment of high-
altitude illness. Chest 2008; 133: 744-55.
35. Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide
in the prophylaxis and treatment of acute mountain sickness.
J Appl Physiol 2007;102:1313-22.
36. Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or
dexamethasone use versus placebo to prevent acute
mountain sickness on Mount Rainier. West J Med 1991; 154:
289-93.
37. Johnson TS, Rock PB, Fulco CS, Trad LA, Spark RF, Maher JT.
Prevention of acute mountain sickness by dexamethasone.
N Engl J Med 1984; 310: 683-6.
38. Guðbergsson H. Háfjallaveiki. Útivera 2006; 4.
39. Bartsch P, Maggiorini M, Ritter M, Noti C, Vock P, Oelz O.
Prevention of high-altitude pulmonary edema by nifedipine.
N Engl J Med 1991; 325:1284-9.
40. Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both
tadalafil and dexamethasone may reduce the incidence of
high-altitude pulmonary edema: a randomized trial. Ann
Intem Med 2006; 145: 497-506.
41. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the
prevention of high-altitude pulmonary edema. N Engl J
Med 2002; 346:1631-6.
42. Sartori C, Duplain H, Lepori M, et al. High altitude impairs
nasal transepithelial sodium transport in HAPE-prone
subjects. Eur Respir J 2004; 23: 916-20.
43. Ferrazzini G, Maggiorini M, Kriemler S, Bartsch P, Oelz
O. Successful treatment of acute mountain sickness with
dexamethasone. Br Med J (Clin Res Ed) 1987; 294:1380-2.
44. Oelz O, Maggiorini M, Ritter M, et al. Nifedipine for high
altitude pulmonary oedema. Lancet 1989; 2:1241-4.
45. Pollard AJ, Murdoch DR. The High Altitude Medicine
Handbook. Radcliff Medicine Press, Oxford 1997.
High altitude sickness - review
High altitude sickness is a common name for illnesses
that can occur at high altitude, usually above 3000
meters from sea level. The cause is hypoxia but the
pathophysiology of the diseases is a complex mixture of
multiple factors, involving the human response to hypoxia.
The most common symptom is headache, but loss of
appetite, nausea and sleep disturbances are also common
complaints. With rapid or high ascent there is increased
risk of acute mountain sickness, with severe headache that
responds poorly to pain medications, nausea, vomiting and
extreme fatigue as the most common symptoms. The most
Gudmundsson G, Gudbjartsson T.
High altitude sickness - review. Icel Med Journal 2009; 95; 441-7
severe forms of high-altitude sickness are high altitude
cerebral edema and high altitude pulmonary edema. High
altitude sickness can be prevented by slow ascent and
avoiding overexertion. Medications can also be used to
reduce symptoms.
In this overview high altitude physiology and
acclimatisation are reviewed. The main types of high
altitude sickness are described with special emphasis on
symptoms and diagnosis, but treatment and prevention are
also reviewed.
Key words: High altitude sickness, acute mountain sickness, high altitude cerebral edema, high altitude pulmonary edema, treatment,
prevention.
Correspondence: Gunnar Guðmundsson, ggudmund@landspitali.is
Barst: 10. desember 2008, - samþykkt til birtingar: 11. maí 2009.
LÆKNAblaðið 2009/95 447
ENGLISH SUMMARY